Chronic Obstructive Pulmonary Disease Treatment Market Value to Reach US$ 25,059.1 Mn by 2026

Innovations in Combination Therapy to Dominate COPD Treatment Market

The chronic obstructive pulmonary disease treatment market is projected to be valued at ~US$ 26.2 billion in the year 2027. The high prevalence of chronic obstructive pulmonary disease (COPD) and the need for improved treatment options are catalyzing market growth.

To meet the needs of patients, healthcare companies in the COPD treatment market are developing efficacious treatment options in combination therapy. Revenue of combination therapy was valued at ~US$ 9.6 billion in 2018; the highest amongst all the drug classes in the chronic obstructive pulmonary disease treatment market.

With increased research & development, healthcare companies are innovating new triple combination therapies. For instance, in June 2019, AstraZeneca — an English-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere — a pressurized metered dose inhaler with built-in triple combination therapy for patients suffering from moderate to severe COPD in Japan. Stakeholders in the chronic obstructive pulmonary disease treatment market are running continuous clinical trials to meet the primary endpoints of the disease.

Request Sample Of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=73763

chronic obstructive pulmonary disease treatment market infographic

Request the Coronavirus Impact Analysis on this Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73763

Dual and Triple Therapies Minimize Moderate and Severe Exacerbations

With ongoing developments in the chronic obstructive pulmonary disease treatment market, healthcare companies are weighing the responses and combination of therapies in patients. As such, there is a strife between the credibility of dual combination therapy and long acting bronchodilators for treatment in COPD patients.

To achieve greater effectiveness of therapies in the chronic obstructive pulmonary disease treatment market, manufacturers have integrated combinations of bronchodilators to treat patients with moderate to severe COPD. This includes the combination of long acting beta agonist (LABA) with long acting muscarinic antagonist (LAMA). Thus, the LAMA and LABA group of inhalers are considered safe and effective in COPD patients.

Also, triple therapy has shown better outcome in patients as compared to single-agent LAMA monotherapy in the COPD treatment market. Compared with LAMA monotherapy, triple therapy helps to drastically reduce moderate or severe exacerbations. Thus, healthcare companies are making significant improvements to enhance triple therapy against dual therapy LABA/LAMA.

Buy this Research Report Now – https://www.transparencymarketresearch.com/checkout.php?rep_id=73763&ltype=S

Improved Bronchodilators Reduce Reversibility in Patients

Stakeholders in the chronic obstructive pulmonary disease treatment landscape are developing methods to reduce emphysema and the mortality rates of patients. This has instigated the need for combined bronchodilator response (BDR) in patients. Revenue of bronchodilators in the COPD treatment market is estimated to reach a value of ~US$ 5.5 billion by 2027; the second-highest amongst all drug classes. This is why, healthcare professionals are taking regular follow-ups on patients with combined-BDR. However, the results in combined-BDR are associated with greater frequency of exacerbations and symptoms of asthma. Thus, healthcare companies are increasing research to identify patients with asthma-COPD overlaps, and developing treatment alternatives that result in improved outcomes.

Studies published in the European Respiratory Journal stated that, bronchodilator reversibility might not distinguish asthma from COPD. It was also found that, the prevalence of bronchodilator reversibility was higher in patients with COPD than in asthma patients. Thus, with the help of bronchodilator response testing, healthcare companies are developing improved prebronchodilators that minimize the adverse effects in patients.